R
Richard M. Schwartz
Researcher at National Institutes of Health
Publications - 27
Citations - 2504
Richard M. Schwartz is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Vaccination & Virus. The author has an hindex of 18, co-authored 27 publications receiving 1994 citations.
Papers
More filters
Journal ArticleDOI
Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection
Rebecca M. Lynch,Eli Boritz,Emily E. Coates,Adam DeZure,Patrick J Madden,Pamela Costner,Mary E. Enama,Sarah H. Plummer,LaSonji A. Holman,Cynthia S. Hendel,Ingelise J. Gordon,Joseph P. Casazza,Michelle Conan-Cibotti,Stephen A. Migueles,Randall Tressler,Robert T. Bailer,Adrian B. McDermott,Sandeep Narpala,Sijy O'Dell,Gideon Wolf,Jeffrey D. Lifson,Brandie A. Freemire,Robert J. Gorelick,Janardan P. Pandey,Sarumathi Mohan,Nicolas Chomont,Rémi Fromentin,Tae-Wook Chun,Anthony S. Fauci,Richard M. Schwartz,Richard A. Koup,Daniel C. Douek,Zonghui Hu,Edmund V. Capparelli,Barney S. Graham,John R. Mascola,Julie E. Ledgerwood,Vrc Study Team +37 more
TL;DR: A single infusion of mAb VRC01 significantly decreased plasma viremia and preferentially suppressed neutralization-sensitive virus strains, demonstrating the virological effect of this neutralizing antibody and highlighting the need for combination strategies to maintain virus suppression.
Journal ArticleDOI
A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA
Katie J. Ewer,Tommy Rampling,N Venkatraman,Georgina Bowyer,Daniel B. Wright,Teresa Lambe,Egeruan B. Imoukhuede,Ruth O. Payne,Sarah Katharina Fehling,Thomas Strecker,Nadine Biedenkopf,Verena Krähling,Claire M. Tully,Nick J. Edwards,Emma M. Bentley,Dhanraj Samuel,Geneviève M. Labbé,Jing Jin,Malick M. Gibani,Alice Minhinnick,Morven Wilkie,Ian D. Poulton,Natalie Lella,Rachel Roberts,Felicity Hartnell,Carly M. Bliss,Kailan Sierra-Davidson,Jonathan Powlson,Eleanor Berrie,Richard S. Tedder,François Roman,Iris De Ryck,Alfredo Nicosia,Nancy J. Sullivan,Daphne A. Stanley,Olivier Tshiani Mbaya,Julie E. Ledgerwood,Richard M. Schwartz,Loredana Siani,Stefano Colloca,Antonella Folgori,Stefania Di Marco,Riccardo Cortese,Edward Wright,Stephan Becker,Barney S. Graham,Richard A. Koup,Myron M. Levine,Ariane Volkmann,Paul Chaplin,Andrew J. Pollard,Simon J. Draper,W. Ripley Ballou,Alison M. Lawrie,Sarah C. Gilbert,Adrian V. S. Hill +55 more
TL;DR: The chimpanzee adenovirus 3 (ChAd3) vaccine boosted with MVA elicited B-cell and T-cell immune responses to ZEBOV that were superior to those induced by the ChAd3 vaccine alone.
Journal ArticleDOI
Chimpanzee Adenovirus Vector Ebola Vaccine
Julie E. Ledgerwood,Adam DeZure,Daphne A. Stanley,Emily E. Coates,Laura Novik,Mary E. Enama,Nina M. Berkowitz,Zonghui Hu,Gyan Joshi,Aurélie Ploquin,Sandra Sitar,Ingelise J. Gordon,Sarah A. Plummer,LaSonji A. Holman,Cynthia S. Hendel,Galina Yamshchikov,François Roman,Alfredo Nicosia,Stefano Colloca,Riccardo Cortese,Robert T. Bailer,Richard M. Schwartz,Mario Roederer,John R. Mascola,Richard A. Koup,Nancy J. Sullivan,Barney S. Graham +26 more
TL;DR: In this paper, a replication-defective recombinant chimpanzee adenovirus type 3-vectored ebolavirus vaccine (cAd3-EBO), encoding the glycoprotein from Zaire and Sudan species, was rapidly advanced into phase 1 clinical evaluation.
Journal ArticleDOI
Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials
Martin R. Gaudinski,Katherine V. Houser,Kaitlyn M. Morabito,Zonghui Hu,Galina Yamshchikov,Ro Shauna S Rothwell,Nina M. Berkowitz,Floreliz Mendoza,Jamie G. Saunders,Laura Novik,Cynthia S. Hendel,LaSonji A. Holman,Ingelise J. Gordon,Josephine H. Cox,Srilatha Edupuganti,Monica A. McArthur,Nadine Rouphael,Kirsten E. Lyke,Ginny E. Cummings,Sandra Sitar,Robert T. Bailer,Bryant M. Foreman,Katherine E. Burgomaster,Rebecca S. Pelc,David N. Gordon,Christina R. DeMaso,Kimberly A. Dowd,Carolyn M. Laurencot,Richard M. Schwartz,John R. Mascola,Barney S. Graham,Theodore C. Pierson,Julie E. Ledgerwood,Grace L. Chen,Sarah H. Plummer,Pamela Costner,Kathryn Zephir,Joseph P. Casazza,Abidemi Ola,Milalynn Victorino,Carol Levinson,William Whalen,Xiaolin Wang,Jennifer Cunningham,Olga Vasilenko,Maria Burgos Florez,Somia P. Hickman,Iris Pittman,Lam Le,Brenda Larkin,Charla A. Andrews,Preeti Apte,Renunda Hicks,Cora Trelles Cartagena,Pernell Williams,Catina R. Boyd,Michelle Conan-Cibotti,Judy Stein,Florence Kaltovich,Hope DeCederfelt,Stacey McAdams,Phyllis Renehan,Wilbur Chen,Nancy Greenberg,Nancy Wymer,Linda Wadsworth,Melissa Billington,Toni Robinson,Colleen Boyce,Faith Pa'ahana Brown,Lisa Chrisley,Alyson Kwon,Prashant Patel,Panagoita Kominou,Brenda Dorsey,Staci Eddington,Shinyi Telscher,Myoughee Lee,Regina Mosely,April Ross,Geoffrey Ford,Briyana Domjahn,Jianguo Xu,Allison Beck,Rebecca Fineman,Shiela Heeke,Jean Winter,Shashi Nagar,Colleen F. Kelley,Mark J. Mulligan +89 more
TL;DR: Both DNA vaccines expressing premembrane and envelope Zika virus structural proteins were safe and well tolerated and followed up volunteers for 24 months for safety and immunogenicity, respectively.
Journal ArticleDOI
Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial
Lee-Jah Chang,Kimberly A. Dowd,Floreliz Mendoza,Jamie G. Saunders,Sandra Sitar,Sarah H. Plummer,Galina Yamshchikov,Uzma N. Sarwar,Zonghui Hu,Mary E. Enama,Robert T. Bailer,Richard A. Koup,Richard M. Schwartz,Wataru Akahata,Gary J. Nabel,John R. Mascola,Theodore C. Pierson,Barney S. Graham,Julie E. Ledgerwood +18 more
TL;DR: The chikungunya VLP vaccine was immunogenic, safe, and well tolerated, and represents an important step in vaccine development to combat this rapidly emerging pathogen.